| Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
| 1996 | Exploitation of frequent p16 deletion in the treatment of T cell acute lymphoblastic leukemia | Yu, A. L.; Chen, J.; Diccianni, M. B.; Batova, A.; Yu, J | In: Molecular Biology of Hematopoiesis 5, Nader G. Abraham, S. Asano, G. Brittenger, R. Shadduck (eds.), Plenum Press, New York 247-256 | | | |
| 1997 | Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia (T-ALL) | Batova, A.; Diccianni, M. B.; Yu, J. C.; Nobori, T.; Link, M. P.; Pullen, J.; Yu, A. L. | Cancer Res 57, 832-836 | | | |
| 1996 | Frequent delection in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: Strategies for enzyme-targeted therapy | Batova, A.; Diccianni, M. B.; Nobori, T.; Vu, T.; Yu, J.; Bridgeman, L.; Yu, A. L. | Blood 88, 3083-3090 | | | |
| 2000 | In vitro sensitivity of T-cell lymphoblastic leukemia to UCN-01 (7-hydroxy staurosporine) in dependent on p16 protein status: a pediatric oncology group study | Omura-Minamisawa, M.; Diccianni, M. B.; Batova, A.; Chang, R. C.; Bridgeman, L. J.; Yu, J.; de Wit, E.; Kung, F. H.; Pullen, J.; Yu, A. L. | Cancer Res 60, 6573-6576 | | | |
| 1999 | Methylation of p16INK4A in primary gynecologic malignancy | Wong, Y. F.; Chung, T. K. H.; Cheung, T. H.; Nobori, T.; Yu, A.; Yu, J.; Batova, A.; Lai, K. W. H.; Chang, A. M. Z. | Cancer Letter 136, 231-235 | | | |
| 1997 | Presence of methylthioadenosine phosphorylase (MTAP) in hematopoietic stem/progenitor cells: Its therapeutic implication for MTAP (-) malignancies | Yu, J.; Batova, A.; Shao, L. E.; Carrera, C. J.; Yu, A. L. | Clin. Cancer Res 3, 433-438 | | | |
| 1997 | Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions | Diccianni, M. B.; Batova, A.; Yu, J.; Vu, T.; Pullen, J.; Amylon, M.; Pollock, B.; Yu, A. L. | Leukemia Res 21, 549-558 | | | |
| 2002 | The histone deacetylase inhibitor AN-9 has selective toxicity to drug-resistant primary leukemia and cancer cell lines | Batova, A.; Shao, L. E.; Diccianni, M. B.; Yu, A. L.; Tanaka, T.; Rephaeli, A.; Nudelman, A.; Yu, J. | Blood 100, 3319-3324 | | | |
| 2000 | Universal inactivation of both p16 and p15 but not downstream components is an essential event in pathogenesis of T-cell acute lymphoblastic leukemia | Omura-Minamisawa, M.; Diccianni, M. B.; Batova, A.; Chang, R. C.; Bridgeman, L.; Yu, J.; Pullen, J.; Bowman, W. P.; Yu, A. L. | CLINICAL CANCER RESEARCH 6, 1219-1228 | | | |
| 1999 | Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro | Batova, A.; Diccianni, M. B.; Yu, J.; Carrera, C. J.; Bridgeman, L. J.; Kung, F. H.; Pullen, J.; Amylon, M. D.; Yu, A. L. | Cancer Research 59, 1492-1497 | | | |
